Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial

医学 川崎病 临床终点 入射(几何) 内科学 环孢素 冠状动脉疾病 临床试验 不利影响 随机对照试验 胃肠病学 外科 动脉 化疗 光学 物理
作者
Hiromichi Hamada,Hiroyuki Suzuki,Yoshihiro Onouchi,Ryota Ebata,Masaru Terai,Shigeto Fuse,Yoshitomo Okajima,Shunji Kurotobi,Katsuki Hirai,Takashi Soga,Yukiko Ishiguchi,Yoshiaki Okuma,Nobuyuki Takada,Masaaki Yanai,Junichi Sato,Mami Nakayashiro,Mamoru Ayusawa,Eiichi Yamamoto,Yuichi Nomura,Yuya Hashimura
出处
期刊:The Lancet [Elsevier BV]
卷期号:393 (10176): 1128-1137 被引量:195
标识
DOI:10.1016/s0140-6736(18)32003-8
摘要

Background Genetic studies have indicated possible involvement of the upregulated calcium-nuclear factor of activated T cells pathway in the pathogenesis of Kawasaki disease. We aimed to assess safety and efficacy of ciclosporin, an immunosuppressant targeting this pathway, for protection of patients with Kawasaki disease against coronary artery abnormalities. Methods We did a randomised, open-label, blinded endpoints trial involving 22 hospitals in Japan between May 29, 2014, and Dec 27, 2016. Eligible patients predicted to be at higher risk for intravenous immunoglobulin (IVIG) resistance were randomly assigned to IVIG plus ciclosporin (5 mg/kg per day for 5 days; study treatment) or IVIG (conventional treatment) groups, stratified by risk score, age, and sex. The primary endpoint was incidence of coronary artery abnormalities using Japanese criteria during the 12-week trial, assessed in participants who received at least one dose of study drug and who visited the study institution at least once during treatment. This trial is registered to Center for Clinical Trials, Japan Medical Association, number JMA-IIA00174. Findings We enrolled 175 participants. One patient withdrew consent after enrolment and was excluded and one patient (in the study treatment group) was excluded from analysis because of lost echocardiography data. Incidence of coronary artery abnormalities was lower in the study treatment group than in the conventional treatment group (12 [14%] of 86 patients vs 27 [31%] of 87 patients; risk ratio 0·46; 95% CI 0·25–0·86; p=0·010). No difference was found in the incidence of adverse events between the groups (9% vs 7%; p=0·78). Interpretation Combined primary therapy with IVIG and ciclosporin was safe and effective for favourable coronary artery outcomes in Kawasaki disease patients who were predicted to be unresponsive to IVIG. Funding Japan Agency for Medical Research and Development (grant CCT-B-2503).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ssk发布了新的文献求助10
1秒前
1秒前
danny完成签到,获得积分10
1秒前
NN的应助被小邹采纳,获得10
2秒前
2秒前
3秒前
饲料批发的应助被川沧采纳,获得10
4秒前
姚序东完成签到,获得积分10
4秒前
5秒前
5秒前
6秒前
号左左发布了新的文献求助50
6秒前
九九发布了新的文献求助10
7秒前
8秒前
xing_xing的应助被曾经的剑身采纳,获得20
8秒前
超级无敌发布了新的文献求助10
8秒前
zzz发布了新的文献求助10
8秒前
yz1005完成签到,获得积分10
8秒前
Lucas的应助被胡萝卜卜采纳,获得10
8秒前
反证谁能想的到完成签到,获得积分10
9秒前
10秒前
研友_nongdalyl完成签到,获得积分10
10秒前
11秒前
12秒前
榴莲气泡水完成签到 ,获得积分10
14秒前
14秒前
今后的应助被DionysusR采纳,获得10
14秒前
YY关注了科研通微信公众号
14秒前
ttttttt发布了新的文献求助10
15秒前
16秒前
香蕉觅云的应助被rachel采纳,获得10
16秒前
promise发布了新的文献求助10
16秒前
盛小珊完成签到,获得积分10
17秒前
齐xia完成签到 ,获得积分10
18秒前
William_l_c发布了新的文献求助50
18秒前
ff发布了新的文献求助10
18秒前
Akim的应助被Libra采纳,获得10
18秒前
zhanglx66完成签到 ,获得积分10
19秒前
20秒前
WU哇哇完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191140
求助须知:如何正确求助?哪些是违规求助? 9578110
关于积分的说明 21856695
捐赠科研通 7790440
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560328
邀请新用户注册赠送积分活动 2483288